Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 37

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 37
---
 of Regulation S-K, the following table presents information regarding stock options granted to our NEOs in 2024 during any period beginning four business days before the filing of Form 10-K or Form 10-Q, or the filing or furnishing of a Form 8-K that discloses material nonpublic information (other than a Form 8-K disclosing a material new option grant under Item 5.02(e)), and ending one business day after the filing or furnishing of such report with the SEC.

|                      |     | Grant date(1) |     | Number of securities underlying the award |           |     | Exercise price per share |      |     | Grant Date fair value of the award |           |     | Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information |
|:---------------------|:----|:--------------|:----|:------------------------------------------|----------:|:----|:-------------------------|-----:|:----|:-----------------------------------|----------:|:----|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Brian M. Culley      |     | 3/7/2024      |     |                                           | 1,900,000 |     | $                        | 1.13 |     | $                                  | 1,502,900 |     | 15.0%                                                                                                                                                                                                                                                                                          |
| Jill A. Howe         |     | 3/7/2024      |     |                                           |   650,000 |     | $                        | 1.13 |     | $                                  |   514,150 |     | 15.0%                                                                                                                                                                                                                                                                                          |
| George A. Samuel III |     | 3/7/2024      |     |                                           |   650,000 |     | $                        | 1.13 |     | $                                  |   514,150 |     | 15.0%                                                                                                                                                                                                                                                                                          |

(1) Each stock option vests with respect to 25% of the number of shares subject to such stock option one year following the grant date and the balance vests in 36 monthly installments thereafter, in each case, subject to the recipient’s continuous service.

<div align='center'>-26-</div>

Consideration of Shareholder Advisory Vote on Executive Compensation

The results of the advisory vote of our shareholders on the compensation of